Dr Reddys launches Carmustine for Injection in US

Hyderabad: Pharma major, Dr Reddy's Laboratories Ltd., has recently announced the launch of Carmustine for Injection, USP.

The product is a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

Carmustine for injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:

• Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors 

• Multiple myeloma-in combination with prednisone 

• Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs 

• Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs

Dr. Reddy's Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.

The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.

BiCNU is a trademark owned or licensed by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc

Read also: First in India: Dr Reddys launches Minoxidil to treat female pattern hair loss